Citations

Clear

6273 citation(s) found for "To, Andrew".

Determinants Of Symptom Presentation And Resolution Following Concussions In High School Sports
Boltz, Adrian J. , Lempke, Landon B. , Rao, Neel , Northam, Weston T. , Collins, Christy L. , Chandran, Avinash S. , Alexander, Andrew S., DiPietro, Loretta

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 984-985

10.1249/01.mss.0000989000.69943.c8 Get It

Cross-validation Of The Army’s Body Fat Percent Estimation Formula Using A Three-compartment Model
Dobbs, Ward C. , Luedke, Joel, Carpenter, Makenna, Jacobson, Anna K., Schmitt, Rachel, Marquardt, Adriana, Jagim, Andrew R. , Almonroeder, Thomas Gus

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 370-371

10.1249/01.mss.0000983252.13761.ea Get It

Pre-workout Beetroot Juice Combined With Supervised Exercise Training Enhances Functional Capacity In Older Women
Blechschmid, Tyler H. , Long, Emily B. , Raglin, John S. , Baranauskas, Marissa N. , Wiggins, Chad C. , Gruber, Allison H. , Coggan, Andrew R. , Carter, Stephen J.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 561-561

10.1249/01.mss.0000985072.78238.93 Get It

Risk of post-sphincterotomy bleeding in patients with thrombocytopenia
AbiMansour, Jad P. , Garimella, Vishal, Petersen, Bret T. , Law, Ryan , Martin, John A. , Levy, Michael J. , Law, Ryan J, AbiMansour, Jad , Petersen, Bret T. , Storm, Andrew C. , Dayyeh, Barham K. Abu , Chandrasekhara, Vinay

Mayo Clinic

Therapeutic Advances in Gastrointestinal Endoscopy | September 25, 2023 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/26317745231200971 | PMID 37767287 Get It

Background: Reports suggest that the rate of adverse events (AEs) post-endoscopic sphincterotomy (ES) to be as high as 10%, with gastrointestinal bleeding being most common after post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Objective: The aim of this study was to characterize the incidence of bleeding in patients with thrombocytopenia following ES. Design: Retrospective observational cohort study. Methods: Patients with thrombocytopenia (defined as <150,000 platelets/μL) who underwent ES between May 2017 and December 2020 were identified at a tertiary care medical center. The incidence of immediate (intraprocedural oozing >5 min or requiring intervention) or delayed (clinical bleeding with associated hemoglobin drop within 14 days) post-ES bleeding was determined via manual chart review. Results: A total of 221 patients with a mean platelet count of 108,000 ± 13,000 platelets/μL underwent ERCP with ES. Immediate bleeding occurred in 11 (5%) patients with no significant drop in hemoglobin or transfusion requirement. Two patients (0.9%), both of whom were noted to have immediate bleeding, also developed delayed bleeding. Presence of malignancy was associated with an increased risk of bleeding (36.4% versus 11.4%, p = 0.037) while platelet count was not. Conclusion: In a cohort of patients with thrombocytopenia, rates of immediate and delayed bleeding are similar to previously reported AE rates of ES in the general patient population. Careful attention should be given to patients with a history of active malignancy as well as those who develop immediate bleeding as they appear to be at increased risk for bleeding complications.
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network
Wagemann, Olivia , Li, Yan , Hassenstab, Jason , Aschenbrenner, Andrew J. , Gordon, Brian A. , Xiong, Chengjie , Perrin, Richard J. , Berman, Sarah , Chhatwal, Jasmeer P. , Farlow, Martin R. , Day, Gregory S. , Mori, Hiroshi , Noble, James M. , Morris, John C. , Daniels, Alisha , Xiong, Chengjie , Network, the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Daniels, Alisha , Berman, Sarah , Noble, James M , McKay, Nicole S. , Benzinger, Tammie L.S. , Xiong, Chengjie , Cruchaga, Carlos , Renton, Alan , Ikeuchi, Takeshi , Jucker, Mathias , Lopera, Francisco Javier , Sánchez‐Valle, Raquel , Schofield, Peter R. , Bateman, Randall J. , McDade, Eric , Llibre‐Guerra, Jorge J. , Network, the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | September 23, 2023 | Volume: 20 | Issue: 1 | Pages: 47-62

10.1002/alz.13460 | PMID 37740921 Get It

AbstractINTRODUCTIONStudies suggest distinct differences in the development, presentation, progression, and response to treatment of Alzheimer's disease (AD) between females and males. We investigated sex differences in cognition, neuroimaging, and fluid biomarkers in dominantly inherited AD (DIAD).METHODSThree hundred twenty‐five mutation carriers (55% female) and one hundred eighty‐six non‐carriers (58% female) of the Dominantly Inherited Alzheimer Network Observational Study were analyzed. Linear mixed models and Spearman's correlation explored cross‐sectional sex differences in cognition, cerebrospinal fluid (CSF) biomarkers, Pittsburgh compound B positron emission tomography (11C‐PiB PET) and structural magnetic resonance imaging (MRI).RESULTSFemale carriers performed better than males on delayed recall and processing speed despite similar hippocampal volumes. As the disease progressed, symptomatic females revealed higher increases in MRI markers of neurodegeneration and memory impairment. PiB PET and established CSF AD markers revealed no sex differences.DISCUSSIONOur findings suggest an initial cognitive reserve in female carriers followed by a pronounced increase in neurodegeneration coupled with worse performance on delayed recall at later stages of DIAD.
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions
Wang, Minggui , Ge, Lizhao , Chen, Liang , Komarow, Lauren , Hanson, Blake , Cober, Eric , Alenazi, Thamer H. , Xie, Qing , Liu, Zhengyin , Li, Lanjuan , Yu, Yunsong , Gao, Hainv , Figueroa, Jairo, Herc, Erica , Córdova, Ezequiel , Weston, Gregory , Kaye, Keith S. , Dhar, Sorabh , Munita, José M. , Salata, Robert A. , Vilchez, Samuel, Stryjewski, Martín E. , Iovleva, Alina , Evans, Scott , Baum, Keri, Hill, Carol , Kreiswirth, Barry N. , Patel, Robin , Arias, Cesar A, Chambers, Henry F. , Fowler, Vance G. , Satlin, Michael J. , Investigators, Multi-Drug Resistant Organism Network, Zhang, Fujie , Castelnuovo, Valentina Di, Gutierrez, Jose Millan Oñate, Evans, Beth , Cross, H. R. , Arias, Rebekka M. , Fowler, Vance G, Ordóñez, Karen , Li, Linghua , Kreiswirth, Barry N , Desai, Samit, Rioseco, María Luisa, Vilchez, Samuel, Sánchez, Marisa , Valderrama, Sandra , Figueroa, Jairo, Arias, Cesar A, Dinh, An Q , Panesso, Diane, Rydell, Kirsten, Tran, Truc T. , Jiang, Jianping , Xu, Xiaogang , Spencer, María, Marshall, Steven H. , Rudin, Susan D., Greenwood-Quaintance, Kerry, Schmidt-Malan, Suzannah M., Revolinski, Sara , Wortmann, Glenn , Kalayjian, Robert C. , Ostrowsky, Belinda , Patel, Gopi , Eiras, Daniel , Garcia-Diaz, Julia, Farrell, John J. , Paterson, David L, Kaye, Keith S, Waters, Mary Jo, Eilertson, Brandon , Ng, Oon Tek , De, Partha Pratim, Chew, Kean Lee , Smitasin, Nares , Gallagher, Jason C , Leroi, Marcel , McCarty, Todd P , Lautenbach, Ebbing , Hanson, Blake, Perez, Federico, Banerjee, Ritu , Dhar, Sorabh, Westblade, Lars F. , Yu, Yunsong , Cordova, Ezequiel , Kaye, Keith S , Evans, Scott R , Patel, Robin , van Duin, David , Pérez, Federico , Jiang, Jianping , Chen, Liang , Wang, Minggui , Munita, Jose M , Reyes, Jinnethe , Zong, Zhiyong , Kanj, Souha S. , Tambyah, Paul Anantharajah , Garcia‐Diaz, Julia , Villegas, María Virginia , Kreiswirth, Barry N , Paterson, David L. , Arias, Cesar A, Bonomo, Robert A. , Fowler, Vance G. , Doi, Yohei , Investigators, Multi-Drug Resistant Organism Network, Lok, Judith J. , Richter, Susan, Anderson, Deverick J. , Evans, Beth, Cross, Heather R, Fowler, Vance G, Jacob, Jesse T. , Manca, Claudia , Vilchez, Samuel, Figueroa, Jairo, Arias, Cesar A, Hu, Fupin , Su, Jiachun , Wang, Minggui, Xu, Xiaogang, Yang, Yang, Huskins, W. Charles , Greenwood‐Quaintance, Kerryl E. , Kim, Angela , Garcia-Diaz, Julia, Salcedo, Soraya , Henderson, Andrew , Paterson, David L, Kaye, Keith S, Fries, Bettina C. , Marimuthu, Kalisvar , Peleg, Anton Yariv , Xiao, Yonghong , Garner, Omai B. , Abbo, Lilian M. , Han, Jennifer , Wong, Darren , Hanson, Blake, Díaz, Lorena

Mayo Clinic

Clinical Infectious Diseases | September 22, 2023 | Volume: 78 | Issue: 2 | Pages: 248-258

10.1093/cid/ciad556 | PMID 37738153 Get It

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb. Methods In a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled at 46 hospitals in five global regions between 2017 and 2019. The primary outcome was all-cause mortality at 30 days from the index culture. The strains underwent whole-genome analysis. Results Of 842 cases, 536 (64%) represented infection. By 30 days, 128 (24%) of the infected patients died, ranging from 1 (6%) of 18 in Australia-Singapore to 54 (25%) of 216 in the United States and 24 (49%) of 49 in South-Central America, whereas 42 (14%) of non-infected patients died. Bacteremia was associated with a higher risk of death compared with other types of infection (40 [42%] of 96 vs 88 [20%] of 440). In a multivariable logistic regression analysis, bloodstream infection and higher age-adjusted Charlson comorbidity index were independently associated with 30-day mortality. Clonal group 2 (CG2) strains predominated except in South-Central America, ranging from 216 (59%) of 369 in the United States to 282 (97%) of 291 in China. Acquired carbapenemase genes were carried by 769 (91%) of the 842 isolates. CG2 strains were significantly associated with higher levels of meropenem resistance, yet non-CG2 cases were over-represented among the deaths compared with CG2 cases. Conclusions CRAb infection types and clinical outcomes differed significantly across regions. Although CG2 strains remained predominant, non-CG2 strains were associated with higher mortality. Clinical Trials Registration. NCT03646227.
Recommendations for Centers Performing Pediatric Heart Surgery in the United States
Backer, Carl L., Overman, David M. , Romano, Jennifer C., Tweddell, James S., Marino, Bradley S. , Bacha, Emile , Jaquiss, Robert, Zaidi, Ali N. , Gurvitz, Michelle , Costello, John M. , Pierick, Trudy A. , Ravekes, William, Reagor, James A. , Spaeth, James P., Mahle, William T. , Shin, Andrew Y. , Karamlou, Tara , Welke, Karl F. , Bryant, Roosevelt , Husain, S. Adil , Chen, Jonathan M., Wells, Winfield J., Glatz, Andrew C. , McElhinney, Doff B. , Parra, David , Pasquali, Sara K. , McElhinney, Doff B , Dearani, Joseph A. , Kumar, S. Ram , Jaquiss, Robert D.B. , Louis, James D. St. , Lopez, Keila N. , Kaza, Aditya K.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | September 22, 2023 | Volume: 14 | Issue: 5 | Pages: 642-679

10.1177/21501351231190353 | PMID 37737602 Get It

Care and outcomes for the more than 40,000 patients undergoing pediatric and congenital heart surgery in the United States annually are known to vary widely. While consensus recommendations have been published across numerous fields as one mechanism to promote a high level of care delivery across centers, it has been more than two decades since the last pediatric heart surgery recommendations were published in the United States. More recent guidance is lacking, and collaborative efforts involving the many disciplines engaged in caring for these children have not been undertaken to date. The present initiative brings together professional societies spanning numerous care domains and congenital cardiac surgeons, pediatric cardiologists, nursing, and other healthcare professionals from diverse programs around the country to develop consensus recommendations for United States centers. The focus of this initial work is on pediatric heart surgery, and it is recommended that future efforts focus in detail on the adult congenital population. We describe the background, rationale, and methodology related to this collaborative effort, and recommendations put forth for Essential Care Centers (essential services necessary for any program), and Comprehensive Care Centers (services to optimize comprehensive and high-complexity care), encompassing structure, process, and outcome metrics across 14 domains.
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Desai, Sanjal H. , Evens, Andrew M. , Šýkorová, Alice , Bachanová, Veronika , Goyal, Gaurav , Dorritie, Kathleen , Azzi, Jacues, Kenkre, Vaishalee P. , Chang, Cheryl , Michalka, Jozef , Ansell, Stephen M. , Fusco, Brendon , Hatic, Haris, Saba, Raya , Harris, Elyse I., Wagner‐Johnston, Nina D. , Arai, Sally , Nowakowski, Grzegorz S. , Móciková, Heidi , Jagadeesh, Deepa , Blum, Kristie A. , Diefenbach, Catherine , Iyengar, Siddharth , Rappazzo, Katherine , Choi, Yun Young , Advani, Ranjana H. , Micallef, Ivana N. , Evens, Andrew M , Goyal, Guarav , Dorritie, Kathleen , Sumransub, Nuttavut , Ibrahim, Uroosa , Wagner-Johnston, Nina , Arai, Sally , Mocikova, Heidi , Prochazka, Vit , Micallef, Ivana, Bachanova, Veronika , Advani, Ranjana H , Desai, Sanjal , Diefenbach, Catherine S , Spinner, Michael A. , Kahl, Brad S. , Shah, Harsh , Baidoun, Firas , Procházka, Vít

Mayo Clinic

Blood Advances | September 20, 2023 | Volume: 7 | Issue: 23 | Pages: 7295-7303

10.1182/bloodadvances.2023011205 | PMID 37729621 Get It

Abstract In the pre–novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence
Wu, Gongwei , Yoshida, Noriaki , Liu, Jihe , Xiong, Yuan , Heavican‐Foral, Tayla B. , Mandato, Elisa , Nelson, Geoffrey M. , Yang, Lu , Chen, Renee , Jones, M. , Roshal, Mikhail , Zhang, Yanming , Xu, Ran , Jain, Salvia , Leahy, Catharine, Jones, Kristen L. , Stevenson, Kristen E. , Galasso, Natasha, Ganesan, Nivetha , Chang, Tiffany , Wu, Wenchao, Louissaint, Abner , Debaize, Lydie , Cin, Paola Dal , Chan, Wing C. , Sui, Shannan J. Ho , Ng, Samuel Y., Chen, Chun‐Wei , Weinstock, David M. , Zhang, Xiaoyang , Xiong, Yuan , Nelson, Geoffrey M , Yang, Lu , Donovan, Katherine A , Jones, Marcus K , Zhang, Yanming , Xu, Ran , Nirmal, Ajit J , Jain, Salvia , Ganesan, Nivetha , Chang, Tiffany , Dal Cin, Paola , Ho Sui, Shannan J , Feldman, Andrew L , Horwitz, Steven M , Adelman, Karen , Fischer, Eric S , Chen, Chun-Wei , Weinstock, David M , Brown, Myles , Heavican, Tayla B., Liu, Huiyun , Yoon, Hojong , Feldman, Andrew L. , Horwitz, Steven M. , Brown, Myles

Mayo Clinic

Science Translational Medicine | September 20, 2023 | Volume: 15 | Issue: 714 | Pages: No page available

10.1126/scitranslmed.adi7244 | PMID 37729434 Get It

Gene fusions involving tumor protein p63 gene (TP63) occur in multiple T and B cell lymphomas and portend a dismal prognosis for patients. The function and mechanisms of TP63 fusions remain unclear, and there is no target therapy for patients with lymphoma harboring TP63 fusions. Here, we show that TP63 fusions act as bona fide oncogenes and are essential for fusion-positive lymphomas. Transgenic mice expressing TBL1XR1::TP63, the most common TP63 fusion, develop diverse lymphomas that recapitulate multiple human T and B cell lymphomas. Here, we identify that TP63 fusions coordinate the recruitment of two epigenetic modifying complexes, the nuclear receptor corepressor (NCoR)—histone deacetylase 3 (HDAC3) by the N-terminal TP63 fusion partner and the lysine methyltransferase 2D (KMT2D) by the C-terminal TP63 component, which are both required for fusion-dependent survival. TBL1XR1::TP63 localization at enhancers drives a unique cell state that involves up-regulation of MYC and the polycomb repressor complex 2 (PRC2) components EED and EZH2. Inhibiting EZH2 with the therapeutic agent valemetostat is highly effective at treating transgenic lymphoma murine models, xenografts, and patient-derived xenografts harboring TP63 fusions. One patient with TP63 -rearranged lymphoma showed a rapid response to valemetostat treatment. In summary, TP63 fusions link partner components that, together, coordinate multiple epigenetic complexes, resulting in therapeutic vulnerability to EZH2 inhibition.
Early antibody treatment, inflammation, and risk of post-COVID conditions
Heath, Sonya L. , Fukuta, Yuriko , Zhu, Xianming , Baksh, Sheriza , Abraham, Allison G., Habtehyimer, Feben , Shade, David , Ruff, Jessica E. , Ram, Malathi , Laeyendecker, Oliver , Fernández, Reinaldo E. , Patel, Eshan U. , Baker, Owen R. , Cachay, Edward R. , Gerber, Jonathan M. , Forthal, Donald N. , Hammitt, Laura L. , Huamán, Moisés A. , Patel, Bela , Gniadek, Thomas J. , Blair, Janis E. , Lane, Karen , McBee, Nichol , Gawad, Amy L., Das, Piyali, Bloch, Evan M. , Zhu, Xianming , Laeyendecker, Oliver , Patel, Eshan U , Forthal, Donald N , Sutcliffe, Catherine G , Klein, Sabra L , Pekosz, Andrew , Bloch, Evan M , Casadevall, Arturo , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Gebo, Kelly A , Shoham, Shmuel , Currier, Judith S. , Meisenberg, Barry R. , Levine, Adam C , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Anjan, Shweta , Kassaye, Seble , Hanley, Daniel F. , Casadevall, Arturo , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

mBio | September 19, 2023 | Volume: 14 | Issue: 5 | Pages: No page available

10.1128/mbio.00618-23 | PMID 37724870 Get It

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93–3.81]), older age (AOR = 1.32 [1.17–1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02–2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.